EAM
Eventide Asset Management Portfolio holdings
AUM
$5.71B
This Quarter Return
-3.15%
1 Year Return
+51.18%
3 Year Return
+209.28%
5 Year Return
+283.63%
10 Year Return
+1,480.39%
AUM
$5.56B
AUM Growth
+$5.56B
(-6%)
Cap. Flow
+$5.24M
Cap. Flow
% of AUM
0.09%
Top 10 Holdings %
Top 10 Hldgs %
25.14%
Holding
166
New
27
Increased
60
Reduced
40
Closed
11
Top Buys
| 1 |
Transmedics
TMDX
|
$47M |
| 2 |
monday.com
MNDY
|
$32.4M |
| 3 |
Toast
TOST
|
$24.8M |
| 4 |
Axsome Therapeutics
AXSM
|
$24.2M |
| 5 |
Ferguson
FERG
|
$24M |
Top Sells
| 1 |
Doximity
DOCS
|
$132M |
| 2 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
$74M |
| 3 |
Palo Alto Networks
PANW
|
$41.7M |
| 4 |
Apellis Pharmaceuticals
APLS
|
$36.2M |
| 5 |
XIFR
XPLR Infrastructure, LP
XIFR
|
$23.4M |
Sector Composition
| 1 | Healthcare | 41.13% |
| 2 | Technology | 24.88% |
| 3 | Industrials | 14.62% |
| 4 | Consumer Discretionary | 8.5% |
| 5 | Energy | 2.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Neurocrine Biosciences
NBIX
$14.1B
| $15.2M | 0.27% |
135,000
| – | – |
|
102
Sarepta Therapeutics
SRPT
$1.96B
| $14.9M | 0.27% |
122,643
| – | – |
|
103
BioMarin Pharmaceuticals
BMRN
$11.5B
| $14.5M | 0.26% |
164,299
| – | – |
|
104
Xenon Pharmaceuticals
XENE
$3.06B
| $14.1M | 0.25% |
413,906
| – | – |
|
105
BioCryst Pharmaceuticals
BCRX
$1.75B
| $13.9M | 0.25% |
1,970,000
| – | – |
|
|
VRNA
106
Verona Pharma
VRNA
$9.18B
| $13.9M | 0.25% |
+850,000
| New | +$13.9M |
|
107
Element Solutions
ESI
$6.13B
| $13.4M | 0.24% |
683,780
+85,172
| +14% | +$1.67M |
|
|
INZY
108
DELISTED
Inozyme Pharma
INZY
| $13.1M | 0.24% |
+3,125,000
| New | +$13.1M |
|
109
Bruker
BRKR
$4.49B
| $13.1M | 0.24% |
210,365
-10,438
| -5% | -$650K |
|
110
GXO Logistics
GXO
$5.87B
| $12.9M | 0.23% |
220,175
+13
| +0% | +$762 |
|
111
EQT Corp
EQT
$32.8B
| $12.8M | 0.23% |
+316,200
| New | +$12.8M |
|
112
Denali Therapeutics
DNLI
$2.34B
| $12.8M | 0.23% |
621,850
+308,443
| +98% | +$6.36M |
|
113
Ultragenyx Pharmaceutical
RARE
$3.14B
| $12.8M | 0.23% |
359,000
| – | – |
|
114
IDEX
IEX
$12.2B
| $12.1M | 0.22% |
58,292
-2,862
| -5% | -$595K |
|
115
Intellia Therapeutics
NTLA
$1.33B
| $11.8M | 0.21% |
372,665
-120,557
| -24% | -$3.81M |
|
116
Encompass Health
EHC
$12.4B
| $11.4M | 0.21% |
170,108
-19,871
| -10% | -$1.33M |
|
|
RCM
117
DELISTED
R1 RCM Inc. Common Stock
RCM
| $11.1M | 0.2% |
735,705
| – | – |
|
118
EastGroup Properties
EGP
$8.87B
| $11.1M | 0.2% |
66,454
+33,199
| +100% | +$5.53M |
|
119
Ardelyx
ARDX
$1.58B
| $11M | 0.2% |
+2,695,000
| New | +$11M |
|
|
CERE
120
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $10.7M | 0.19% |
490,000
| – | – |
|
121
Korro Bio
KRRO
$208M
| $10M | 0.18% |
+3,597,122
| New | +$10M |
|
122
Revolution Medicines
RVMD
$7.62B
| $9.99M | 0.18% |
361,000
+365
| +0.1% | +$10.1K |
|
123
908 Devices
MASS
$212M
| $9.53M | 0.17% |
1,430,995
| – | – |
|
124
IDEAYA Biosciences
IDYA
$2.33B
| $9.04M | 0.16% |
+335,000
| New | +$9.04M |
|
125
Verisk Analytics
VRSK
$37.2B
| $8.95M | 0.16% |
37,881
-23,195
| -38% | -$5.48M |
|